Lack of pharmacokinetic interaction between remacemide hydrochloride and sodium valproate in epileptic patients

A randomized, double-blind, placebo-controlled cross-over study of adjuvant treatment with remacemide hydrochloride was carried out in 17 patients taking sodium valproate (VPA) as monotherapy. Plasma concentration profiles of VPA, remacemide, and its active desglycinyl metabolite (ARL12495XX) were d...

Full description

Saved in:
Bibliographic Details
Published in:Seizure (London, England) England), 1997-06, Vol.6 (3), p.179-184
Main Authors: Leach, J.P., Girvan, J., Jamieson, V., Jones, T., Richens, A., Brodie, M.J.
Format: Article
Language:English
Subjects:
Acetamides - administration & dosage
Acetamides - adverse effects
Acetamides - pharmacokinetics
Adult
Anticonvulsants - administration & dosage
Anticonvulsants - adverse effects
Anticonvulsants - pharmacokinetics
Cross-Over Studies
Double-Blind Method
drug interaction
Drug Interactions
epilepsy
Epilepsy - drug therapy
Epilepsy - metabolism
Female
Humans
Male
Middle Aged
remacemide hydrochloride
sodium valproate
Valproic Acid - administration & dosage
Valproic Acid - adverse effects
Valproic Acid - pharmacokinetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A randomized, double-blind, placebo-controlled cross-over study of adjuvant treatment with remacemide hydrochloride was carried out in 17 patients taking sodium valproate (VPA) as monotherapy. Plasma concentration profiles of VPA, remacemide, and its active desglycinyl metabolite (ARL12495XX) were determined following single (300 mg) and multiple dosing (150 or 300 mg twice daily) of remacemide hydrochloride for 14 days with a 300-mg final dose. Central nervous system side-effects were more common at the higher dose, which prompted dosage reduction to 150 mg twice daily for subsequent patients partway through the study. The mean area under the concentration-time curve, peak concentration and pre-dose concentration of VPA were unchanged by remacemide hydrochloride in three patients on the higher and in 10 patients on the lower dose of remacemide. The pharmacokinetic parameters of remacemide and its active metabolite in the VPA-treated patients were similar to those described previously in healthy volunteers. Thus, remacemide hydrochloride does not interfere with the pharmacokinetics of VPA and vice versa.
ISSN:1059-1311
1532-2688
DOI:10.1016/S1059-1311(97)80003-9